American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • COVID-19 in patients (pts) with chronic myeloid leukemia (CML): Results from the international CML foundation (iCMLf) CML and COVID-19 (CANDID) study
    Meeting Abstract

    Rea, D.; Mauro, M. J.; Cortes, J. E.; Jiang, Q.; Pagnano, K. B.; Ongondi, M.; Kok, C. H.; Evans, N.; Hughes, T. P.; International CML Foundation
    Blood (2020)

    Fulltext@MSK | Save
  • LSD1 inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation
    Meeting Abstract

    Rampal, R. K.; McGrath, J. P.; Krishnan, A.; Li, B.; Xiao, W.; Nikom, D.; Wang, J.; Levine, R. L.; Trojer, P.
    Blood (2020)

    Fulltext@MSK | Save
  • Prognostic factors for North American adult T cell leukemia lymphoma: Defining risk groups using a four-point score prognostic system
    Meeting Abstract

    Rahman, S.; Soto, A. A.; Qunaj, L.; Ye, K.; Pradhan, K.; Thakkar, A.; Cui, Z.; Meron, M. K.; D'Aiello, A.; Lombardo, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Association of baseline and postinfusion biomarkers with safety and efficacy endpoints in patients treated with orvacabtagene autoleucel (orva-cel; JCARH125) in the phase 1/2 evolve study (NCT03430011)
    Meeting Abstract

    Piasecki, J.; Devries, T.; Radhakrishnan, A.; Li, Y.; Heipel, M.; Fox, B. A.; Beckett, V.; Stirner, M. C.; Conte, K.; Doerr, T.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Pediatric patients with relapsed/refractory acute lymphoblastic leukemia harboring heterogeneous genomic profiles respond to venetoclax in combination with chemotherapy
    Meeting Abstract

    Place, A. E.; Karol, S. E.; Forlenza, C. J.; Gambart, M.; Cooper, T. M.; Fraser, C.; Cario, G.; O'Brien, M. M.; Gerber, N. U.; Barnette, P.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Characteristics and outcomes of newly diagnosed acute myeloid leukemia patients receiving venetoclax combinations vs other therapies: Results from the AML real world evidence (ARC) Initiative
    Meeting Abstract

    Pollyea, D. A.; Stahl, M.; Talati, C.; Asghari, H.; Lai, C.; Abedin, S.; Zeidner, J. F.; Muluneh, B.; Xavier, M.; Edwards, W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A Multicenter, multicohort, open-label, single-arm per cohort, phase II study to assess the efficacy and safety of tabelecleucel in patients with EBV-associated diseases using an adaptive two-stage study design
    Meeting Abstract

    Prockop, S.; Dinavahi, R.; Navarro, W.; Guzman-Becerra, N.; Sun, Y.; Gamelin, L.
    Blood (2020)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial: Dose optimization efficacy update and expansion phase initial results
    Meeting Abstract

    Pro, B.; Brammer, J. E.; Casulo, C.; Jacobsen, E.; Mead, M.; Mehta-Shah, N.; Zain, J. M.; Zinzani, P. L.; Lustgarten, S.; Youssoufian, H.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Costs of postinfusion monitoring by site of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who received third-line or later treatment with lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH trials
    Meeting Abstract

    Palomba, M. L.; Jun, M. P.; Garcia, J.; Lymp, J.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Nguyen, A.
    Blood (2020)

    Fulltext@MSK | Save
  • A phase I study of FT819, a first-of-kind, off-the-shelf, iPSC-derived TCR less CD19 CAR T cell therapy for the treatment of relapsed/refractory b-cell malignancies
    Meeting Abstract

    Park, J. H.; Jain, N.; Chen, A.; McGuirk, J. P.; Diaz, M.; Valamehr, B.; Chu, Y. W.; Castro, J. E.
    Blood (2020)

    Fulltext@MSK | Save